GMED

Acquisition Announcement: Globus Medical, Inc. has completed its acquisition of Nevro Corp., enhancing its presence in the musculoskeletal market and aiming to provide innovative solutions for chronic pain treatment.

Market Potential: The acquisition opens up a $2.5 billion market opportunity for Globus Medical, with plans to discuss the benefits of this expanded product offering in an upcoming earnings conference.

GLOBUS MEDICAL INC Analysis: GLOBUS MEDICAL INC (GMED) has received a 57% rating using the Value Investor model based on Benjamin Graham's strategy, indicating it meets several criteria for low P/B and P/E ratios, low debt, and solid long-term earnings growth.

About Benjamin Graham: Benjamin Graham, known as the "Father of Value Investing," significantly influenced the investment world and mentored notable investors like Warren Buffett, achieving impressive returns during his career despite economic challenges.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Globus Medical (GMED): Analysts maintain a bullish outlook with a Buy rating and a price target of $115.00, indicating a potential upside from the current share price of $71.30.

Phreesia (PHR): The stock also receives a Buy rating with a price target of $29.00, suggesting a 35.9% upside from its current price of $23.80, supported by a Strong Buy consensus among analysts.

Analyst Ratings: RBC Capital analyst Shagun Singh Chadha maintains a Buy rating on Globus Medical with a price target of $101, while Morgan Stanley also issued a Buy rating, contrasting JMP Securities' Hold rating.

Financial Performance: Globus Medical reported a quarterly revenue of $657.29 million and a net profit of $26.51 million for the quarter ending December 31, showing growth compared to last year's revenue of $616.53 million and net profit of $15.03 million.

New Product Launches: Globus Medical has introduced two new products, the COHERE™ ALIF Spacer, a Porous PEEK™ interbody spacer for anterior lumbar interbody fusion surgery, and Modulus™ ALIF Blades, which enhance the versatility of their existing ALIF interbody spacer system.

Advancements in Surgical Efficiency: The new offerings aim to improve surgical outcomes and efficiency by providing innovative solutions that reduce the number of surgical steps and instruments needed, ultimately enhancing patient care in spine surgery.

ETF Analyst Target Prices: The iShares Core S&P U.S. Growth ETF (IUSG) has an implied analyst target price of $163.66, indicating a potential upside of 23.67% from its current trading price of $132.34.

Notable Holdings with Upside Potential: Key underlying holdings such as Kirby Corp., Belden Inc., and Globus Medical Inc. show significant upside potential based on analyst target prices, with increases expected of 39.50%, 27.50%, and 27.49% respectively.

Globus Medical Participation at AAOS 2025: Globus Medical, Inc. will showcase its innovative musculoskeletal technology, including the ExcelsiusFlex™ surgical robotic navigation system and other products, at the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting in San Diego from March 10-14, 2025.

Networking Opportunities: The company invites attendees to a reception on March 12, 2025, and will conduct an investor relations booth tour to discuss their latest technologies and solutions.

Company Announcement: Globus Medical, Inc. will present at the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego on March 10, 2025, at 4:30 pm PT, with a live and archived webcast available on their investor relations website.

About the Company: Globus Medical is a leading musculoskeletal technology company based in Audubon, Pennsylvania, focused on addressing clinical needs and advancing care in various medical fields including spine and orthopedic trauma.

Globus Medical Participation: Globus Medical will showcase its innovative products, including the ExcelsiusFlex™ surgical robotic navigation system, at the AAOS Annual Meeting in San Diego from March 10-14, 2025, located at booth #2517.

Event Highlights: The company will host a reception for attendees and an investor relations booth tour on March 12, providing opportunities to engage with surgeon partners and learn about their latest technologies.

Financial Performance: Nevro Corp. reported a decrease in revenue for Q4 2024, totaling $105.5 million, down 9.1% from the previous year, with a net loss of $51.4 million attributed to increased operating expenses and a goodwill impairment charge.

Acquisition Announcement: Nevro has entered into an agreement for Globus Medical to acquire all shares of the company for approximately $250 million, pending shareholder and regulatory approvals, while also launching new pain management technologies in recent months.

Investigation Announcements: Brodsky & Smith is investigating potential breaches of fiduciary duties by the boards of several companies, including Siyata Mobile Inc., Bridge Investment Group Holdings Inc., Nevro Corp., and 180 Degree Capital Corp., regarding their acquisition agreements and whether shareholders are receiving fair value for their shares.

Legal Representation: The law firm specializes in representing shareholders in securities and class action lawsuits, with a history of successful recoveries for clients, and offers consultations without financial obligation.

Investigation Announcements: Brodsky & Smith is investigating potential breaches of fiduciary duties by the boards of several companies, including Siyata Mobile Inc., Bridge Investment Group Holdings Inc., Nevro Corp., and 180 Degree Capital Corp., regarding their acquisition agreements and whether shareholders are receiving fair value for their shares.

Legal Representation: The law firm specializes in representing shareholders in securities and class action lawsuits, with a history of successful recoveries for clients, and encourages affected shareholders to contact them for discussions on the investigations.

Globus Medical Inc Trading Update: Shares of Globus Medical Inc (GMED) have entered oversold territory with an RSI reading of 28.4, indicating potential exhaustion of recent selling pressure and possible buying opportunities.

Stock Performance Overview: GMED's 52-week range shows a low of $49.33 and a high of $94.93, with the last trade recorded at $79.09.

Price Target Increase: Barclays has raised the price target for Globus Medical (GMED) from $100 to $103, maintaining an Overweight rating due to strong Q4 sales growth and promising future outlook.

Positive Growth Indicators: The firm's record robot placements indicate robust implant pull-through, suggesting that Globus Medical's 2025 projections are reasonable and potentially conservative.

Analyst Ratings on Globus Medical: David Turkaly from JMP Securities has reiterated a Hold rating on Globus Medical, while Needham's David Saxon also issued a Hold. Conversely, Roth MKM maintained a Buy rating for the company.

Insider Activity and Stock Performance: Recent insider activity shows negative sentiment with an increase in share sales by insiders, including a significant sale by Director Dan Lemaitre. The stock has fluctuated between a one-year high of $94.93 and a low of $49.33.

Analyst Ratings: Analysts from Stifel Nicolaus have maintained Buy ratings on Globus Medical, Glaukos, and Alignment Healthcare, with price targets indicating potential upside for each stock.

Market Sentiment: The overall analyst consensus for these companies is Strong Buy, reflecting positive outlooks based on their financial performance and market positions.

Analyst Rating Update: Wells Fargo analyst Vik Chopra has lowered the price target for Globus Medical (GMED) to $93 from $95 while maintaining an Overweight rating, citing a solid Q4 performance in line with expectations.

Future Expectations: The firm anticipates the completion of the Nevro (NVRO) deal by late Q2 and expresses confidence in Globus' ability to integrate Nevro successfully following its previous integration with NuVasive.

Analyst Ratings and Price Targets: Matt Miksic from Barclays maintains a Buy rating on Globus Medical with a price target of $100.00, while the overall analyst consensus suggests a Moderate Buy with an average price target of $98.92, indicating potential upside from current levels.

Financial Performance and Insider Activity: Globus Medical reported significant revenue growth in its latest earnings, but insider sentiment has turned negative, with increased selling activity among company insiders, including a notable sale by Director Dan Lemaitre.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and timely updates.